Gout: objective, indications and adherence to uratelowering therapy
https://doi.org/10.21518/2079-701X-2019-1-72-75
Abstract
Gout is a chronic systemic inflammatory tophus disease with recurrent arthritis of the peripheral joints in patients with hyperuricemia and the deposition of monosodium urate crystals in various tissues. Only 50% or less of patients receive therapy lowering serum uric acid levels to the target level. The lowering therapy is started with a low dose and subsequent titration in all patients with high UA serum levels in the presence of renal pathology, and in such comorbid diseases as hypertension, heart failure, coronary artery disease.
About the Authors
V. V. Tsurko
Federal State Autonomous Educational Institution of Higher Education «I.M. Sechenov First Moscow State Medical University» of the
Ministry of Heath of the Russian Federation (Sechenov University);
Federal State Budgetary Educational Institution of Higher Education «Pirogov Russian National Research Medical University» of the
Ministry of Health of Russia,
Russian Federation
Dr. of Sci. (Med.), Professor, Chair of General Medical Practice, Federal State Autonomous Educational Institution of Higher Education «I.M. Sechenov First Moscow State Medical University» of the Ministry of Heath of the Russian Federation (Sechenov University)
Russian Federation
Dr. of Sci. (Med.), Professor, Chair of General Medical Practice, Federal State Autonomous Educational Institution of Higher Education «I.M. Sechenov First Moscow State Medical University» of the Ministry of Heath of the Russian Federation (Sechenov University)
T. Ye. Morozova
Federal State Autonomous Educational Institution of Higher Education «I.M. Sechenov First Moscow State Medical University» of the
Ministry of Heath of the Russian Federation (Sechenov University)
Russian Federation
Dr. of Sci. (Med.), Professor, Head of Chair of General Medical Practice, Federal State Autonomous Educational Institution of Higher Education «I.M. Sechenov First Moscow State Medical University» of the Ministry of Heath of the Russian Federation (Sechenov University)
Russian Federation
Dr. of Sci. (Med.), Professor, Head of Chair of General Medical Practice, Federal State Autonomous Educational Institution of Higher Education «I.M. Sechenov First Moscow State Medical University» of the Ministry of Heath of the Russian Federation (Sechenov University)
M. A. Gromova
Federal State Budgetary Educational Institution of Higher Education «Pirogov Russian National Research Medical University» of the
Ministry of Health of Russia,
Russian Federation
Cand. of Sci.(Med.), Assistant of Chair of Hospital Therapy, Federal State Budgetary Educational Institution of Higher Education «Pirogov Russian National Research Medical University» of the Ministry of Health of the Russian Federation
Russian Federation
Cand. of Sci.(Med.), Assistant of Chair of Hospital Therapy, Federal State Budgetary Educational Institution of Higher Education «Pirogov Russian National Research Medical University» of the Ministry of Health of the Russian Federation
K. M. Krykhivskaya
Federal State Autonomous Educational Institution of Higher Education «I.M. Sechenov First Moscow State Medical University» of the
Ministry of Heath of the Russian Federation (Sechenov University)
Russian Federation
Dr. of Sci. (Med.), Resident Physician, Chair of General Medical Practice, Federal State Autonomous Educational Institution of Higher Education «I.M. Sechenov First Moscow State Medical University» of the Ministry of Heath of the Russian Fede ration (Sechenov University)
Russian Federation
Dr. of Sci. (Med.), Resident Physician, Chair of General Medical Practice, Federal State Autonomous Educational Institution of Higher Education «I.M. Sechenov First Moscow State Medical University» of the Ministry of Heath of the Russian Fede ration (Sechenov University)
References
1. Maiuolo J., Oppedisano F., Gratteri S. et al. Regulation of uric acid metabolism and excretion. Int. J. Cardiol. 2016;213:8-14, doi: 10.1016/j.ijcard.2015.08.109, indexed in Pubmed: 26316329.
2. Gaffo A.L., Lawrence E.N, Saag K.G. Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link? Arthritis Res. Therapy. 2009;11(Issue 4):240-249.
3. EGIS collected statistics on the prevalence of hyperuricemia in combination with arterial hypertension and comorbidities among Russian patients. Poliklinika. Spetsvypusk. 2017;4:16. (In Russ).
4. Norvik J.V., Storhaug H.M., Ytrehus K. et al. Overweight modifies the longitudinal association between uric acid and some components of the metabolic syndrome: The Tromso Study. BMC Cardiovasc. Disord. 2016;16:85-98.
5. Perlstein T.S., Gumieniak O., Williams G.H. et al. Uric acid and the development of hypertension: the normative aging study. Hypertension. 2006;48(6):1031-1036. doi: 10.1161/01.HYP.0000248752.08807.4c.; indexed in Pubmed: 17060508.
6. Syamala S., Li J., Shankar A. Association between serum uric acid and prehypertension among US adults. J. Hypertens. 2007;25(8):1583-1589, doi: 10.1097/HJH.0b013e32813aeb6c; indexed in Pubmed: 17620953.
7. Vorobiev P.A., Tsurko V.V., Eliseeva M.E. Gout in geriatric practice. Guidelines. Part I. Klin. Gerontol. 2016;3-4(22):3-9. (In Russ).
8. Yeliseev M.S. Urate-lowering therapy: basic principles and real opportunities. Meditsinsky Sovet. 2017;20:144-150. (In Russ).
9. Janssens H.J., van de Lisdonk E.H., Bor H. et al. Gout, just a nasty event or a cardiovascularsignal? A study from primary care. Fam. Pract. 2003;20:413-416.
10. Bhansing K.J., Bon L., Janssen M. et al. Gout: a clinical syndrome illustrated and discussed. Nether. J. Med. 2010;68(9):352-359.
11. Janssens H.J., van de Lisdonk E.H., Janssen M. et al. Gout, not induced by diuretics? A case-control study from primary care. Ann. Rheum. Dis. 2006;65(8):1080-1083.
12. Akkineni R., Tapp S., Tosteson A.N.A. et al. Treatment of asymptomatic hyperuricemia and prevention of vascular disease: a decision analytic approach. J. Rheumatol. 2014;41(4):739-748. doi:10.3899/irheum.l21231; indexed in Pubmed: 24584921.
13. Widecka K., Szymanski F.М., Filipiak K.J. et al. Hyperuricemia and its treatment in patients with a high cardio-vascular risk – experts opinion. Arterial. Hypertens. 2017;21(1):10-17. doi: 10.5603/AH.2017.0002.
14. Tsurko V.V., Gromova M.A., Yeliseyeva M.E. Uratelowering therapy for gout: focus on febuxostat (based on the recommendations of the European Antirheumatic League). Trudny Patsient. 2017;15(3):24-26. (In Russ).
15. Tsurko V.V., Gromova M.A. A rational approach to the treatment of gout, taking into account the onset, course and combined pathology, based on the recommendations of the European Antirheumatic League (EULAR, 2016). Terapevt. Arkhiv. 2017;12(issue 2):233-237. (In Russ).
16. Akkineni R., Tapp S., Tosteson A.N.A. et al. Treatment of asymptomatic hyperuricemia and prevention of vascular disease: a decision analytic approach. J. Rheumatol. 2014;41(4):739-748. doi:10.3899/irheum.l21231: indexed in Pubmed: 24584921.
17. Seth R., Kydd A., Buchbinder R. et al. Allopurinol for chronic gout. Cochrane Database of Systematic Reviews. 2014. doi:10.1002/14651858.cd006077. pub3; indexed in Pubmed:25314636.
18. Schumacher H.R.Jr., Becker M.A., Wortmann R.L. et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallelgroup trial. Arthritis Rheum. 2008;59:1540– 1548.
19. Becker M.A., Schumacher H.R. Jr., Wortmann R.L. et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450–2461.
20. Becker M.A., Schumacher H.R., Espinoza L.R. et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12:R63.
21. Hira D., Chisaki Y., Noda S. et al. Population pharmacokinetics and therapeutic efficacy of febuxostat in patients with severe renal impairment. Pharmacology. 2015;96:90–8.
22. Abeles A.M. Febuxostat hypersensitivity. J. Rheumatol. 2012;39:659.
23. Chohan S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J. Rheumatol. 2011;38:1957–1959.
24. Bardin T., Chalès G., Pascart T. et al. Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment. Joint Bone Spine. 2016;83:314–317.
25. Schumacher H.R.Jr., Becker M.A., Wortmann R.L. et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallelgroup trial. Arthritis Rheum. 2008;59:1540– 1548.
26. Becker M.A., Schumacher H.R., Wortmann R.L., et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N. Engl.J. Med. 2005;353(23):2450-2461. doi: 10.1056/ NEJMoa050373; indexed in Pubmed: 16339094.
Review
For citations:
Tsurko VV, Morozova TY, Gromova MA, Krykhivskaya KM. Gout: objective, indications and adherence to uratelowering therapy. Meditsinskiy sovet = Medical Council. 2019;(1):72-75. (In Russ.) https://doi.org/10.21518/2079-701X-2019-1-72-75
Views:
800
Email this article 